The weekly litigation news digest is live. Subscribe now

IP Verse

Fluticasone Furoate In The Treatment Of Copd

Patent No. EP3650019 (titled "Fluticasone Furoate In The Treatment Of Copd") was filed by Glaxosmithkline on May 27, 2015. The application was issued on Oct 11, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKJun 6, 2024ELKINGTON AND FIFE
SANDOZJun 6, 2024MAIWALD
TEVA PHARMACEUTICALSJun 6, 2024ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3650019

GLAXOSMITHKLINE
Application Number
EP19214674A
Filing Date
May 27, 2015
Status
Granted And Under Opposition
Aug 4, 2023
Publication Date
Oct 11, 2023
External Links
Slate, EP3650019B8, Google Patents